The post Trump reaches drug pricing deal with AstraZeneca appeared on BitcoinEthereumNews.com. U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday. The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month. President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC. Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing. It is unclear if the deal with AstraZeneca would also include such a carveout. AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement. Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S. Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead. “If we don’t make a deal, we’re going to tariff them,” he… The post Trump reaches drug pricing deal with AstraZeneca appeared on BitcoinEthereumNews.com. U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday. The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month. President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC. Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing. It is unclear if the deal with AstraZeneca would also include such a carveout. AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement. Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S. Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead. “If we don’t make a deal, we’re going to tariff them,” he…

Trump reaches drug pricing deal with AstraZeneca

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025.

Nathan Howard | Reuters

The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday.

The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month.

President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC.

Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing.

It is unclear if the deal with AstraZeneca would also include such a carveout.

AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement.

Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S.

Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead.

“If we don’t make a deal, we’re going to tariff them,” he said late last month as he announced the Pfizer agreement.

This story is developing. Please check back for updates.

Source: https://www.cnbc.com/2025/10/10/trump-astrazeneca-drug-pricing-deal.html

Market Opportunity
OFFICIAL TRUMP Logo
OFFICIAL TRUMP Price(TRUMP)
$2.987
$2.987$2.987
-1.35%
USD
OFFICIAL TRUMP (TRUMP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

BlackRock Increases U.S. Stock Exposure Amid AI Surge

BlackRock Increases U.S. Stock Exposure Amid AI Surge

The post BlackRock Increases U.S. Stock Exposure Amid AI Surge appeared on BitcoinEthereumNews.com. Key Points: BlackRock significantly increased U.S. stock exposure. AI sector driven gains boost S&P 500 to historic highs. Shift may set a precedent for other major asset managers. BlackRock, the largest asset manager, significantly increased U.S. stock and AI sector exposure, adjusting its $185 billion investment portfolios, according to a recent investment outlook report.. This strategic shift signals strong confidence in U.S. market growth, driven by AI and anticipated Federal Reserve moves, influencing significant fund flows into BlackRock’s ETFs. The reallocation increases U.S. stocks by 2% while reducing holdings in international developed markets. BlackRock’s move reflects confidence in the U.S. stock market’s trajectory, driven by robust earnings and the anticipation of Federal Reserve rate cuts. As a result, billions of dollars have flowed into BlackRock’s ETFs following the portfolio adjustment. “Our increased allocation to U.S. stocks, particularly in the AI sector, is a testament to our confidence in the growth potential of these technologies.” — Larry Fink, CEO, BlackRock The financial markets have responded favorably to this adjustment. The S&P 500 Index recently reached a historic high this year, supported by AI-driven investment enthusiasm. BlackRock’s decision aligns with widespread market speculation on the Federal Reserve’s next moves, further amplifying investor interest and confidence. AI Surge Propels S&P 500 to Historic Highs At no other time in history has the S&P 500 seen such dramatic gains driven by a single sector as the recent surge spurred by AI investments in 2023. Experts suggest that the strategic increase in U.S. stock exposure by BlackRock may set a precedent for other major asset managers. Historically, shifts of this magnitude have influenced broader market behaviors as others follow suit. Market analysts point to the favorable economic environment and technological advancements that are propelling the AI sector’s momentum. The continued growth of AI technologies is…
Share
BitcoinEthereumNews2025/09/18 02:49
Pound Sterling Plummets: US Dollar Soars on Intensifying Global Risk Aversion

Pound Sterling Plummets: US Dollar Soars on Intensifying Global Risk Aversion

BitcoinWorld Pound Sterling Plummets: US Dollar Soars on Intensifying Global Risk Aversion LONDON, April 2025 – The Pound Sterling has experienced a pronounced
Share
bitcoinworld2026/03/09 13:15
CME to launch Solana and XRP futures options on October 13, 2025

CME to launch Solana and XRP futures options on October 13, 2025

The post CME to launch Solana and XRP futures options on October 13, 2025 appeared on BitcoinEthereumNews.com. Key Takeaways CME Group will launch futures options for Solana (SOL) and XRP. The launch date is set for October 13, 2025. CME Group will launch futures options for Solana and XRP on October 13, 2025. The Chicago-based derivatives exchange will add the new crypto derivatives products to its existing digital asset offerings. The launch will provide institutional and retail traders with additional tools to hedge positions and speculate on price movements for both digital assets. The futures options will be based on CME’s existing Solana and XRP futures contracts. Trading will be conducted through CME Globex, the exchange’s electronic trading platform. Source: https://cryptobriefing.com/cme-solana-xrp-futures-options-launch-2025/
Share
BitcoinEthereumNews2025/09/18 01:07